Polar Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Polar Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-114,000	Closed	-$7.73M	–	263
2017 Q1	$7.73M	Sell	114,000 -217,220	-66%	-$16.6M	0.12%	159
2016 Q4	$23.3M	Buy	331,220 +89,500	+37%	+$6.35M	0.37%	85
2016 Q3	$17.1M	Buy	241,720 +236,803	+4,816%	+$15.1M	0.3%	111
2016 Q2	$240K	Sell	4,917 -8,315	-63%	-$538K	﹤0.01%	262
2016 Q1	$838K	Sell	13,232 -196,768	-94%	-$12.9M	0.02%	240
2015 Q4	$23.6M	Sell	210,000 -85,879	-29%	-$8.59M	0.43%	73
2015 Q3	$28.5M	Buy	295,879 +33,818	+13%	+$3.87M	0.58%	49
2015 Q2	$26.8M	Sell	262,061 -63,467	-19%	-$4.93M	0.52%	59
2015 Q1	$20.2M	Buy	+325,528	New	+$18.1M	0.38%	84

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Polar Capital's RARE Position: Q2 2017 in Review

Polar Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2017, closing a stake of 114,000 shares — an estimated $7.73M sold.

Polar Capital first reported a position in RARE in Q1 2015 and held it in 9 quarters. The position peaked at $28.5M in Q3 2015. 158 funds tracked by Wall St. Rank hold RARE as of Q2 2017.

Polar Capital reported no remaining Ultragenyx Pharmaceutical position as of Q2 2017 after selling out during the quarter.
Polar Capital sold 114,000 Ultragenyx Pharmaceutical shares in Q2 2017, an estimated $7.73M.
Polar Capital first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and held it in 9 quarters.
Polar Capital's Ultragenyx Pharmaceutical position peaked at $28.5M in Q3 2015.
158 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2017.

Based on Polar Capital's 13F filing for Q2 2017, filed 14 Aug 2017.